# Jin Medical International Ltd. (ZJYL)

> Source: Nexqual · https://nexqual.com/ZJYL · data as of 2026-11-18 20:59 UTC · cite as "Nexqual, Jin Medical International Ltd. (ZJYL), nexqual.com/ZJYL" · informational, not investment advice.

## ZJYL major shareholder filing: Schedule 13D/A, Sep 25, 2026
Erqi Wang, JOLLY HARMONY ENTERPRISES Ltd filed a Schedule 13D/A on Sep 25, 2026, reporting up to 3.35% of the class (more than 5% owner that may seek to influence the company). Item 4, Purpose of Transaction, quoted:

> The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting power in the Issuer were diluted as a result of the Issuer's issuance of shares as described in Item 5 below.

Source: https://www.sec.gov/Archives/edgar/data/1837821/000121390026103303/0001213900-26-103303-index.htm

## What changed for ZJYL since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

- Jin Medical International Ltd. (ZJYL) stock went from USD 14.22 (close of the week of Aug 25, 2025, split-adjusted) to USD 3.38, a -76.2% price change; the S&P 500 (SPY) moved +14.7% over the same period.

**Price:** USD 3.39 (+0.30% on the day) · last close of Nov 18, 2026; US market after hours, not a live price. Prev close 3.38 · day 3.29–3.44 · 52w 1.53–5.6 · market cap $539M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -35.4% vs S&P 500 +11.4%; 5Y -54.6% vs S&P 500 +66.5%.
- Dividend: ZJYL paid no cash dividend in the last five years.
- Short interest: 0.01% of float (as of 2026-10-30), 0.0 days to cover.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-19) | 5Y (from 2023-03-27) |
|---|---|---|
| Total return | -35.4% | -54.6% |
| S&P 500 (SPY) | +11.4% | +66.5% |
| Per year | -35.5% | -19.4% |
| Volatility (annualized) | 112.3% | 161.9% |
| Max drawdown | -65.6% (Jan 2026→Jul 2026) | -99.3% (Jan 2024→Mar 2026) |

## Dividends
ZJYL paid no cash dividend in the last five years.

## Short interest
7,541 shares sold short, 0.01% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 70,013 shares (-89.2%). Days to cover: 0.0 (short shares ÷ average daily volume).

## Peers (Medical Instruments & Supplies)
LMAT (LeMaitre Vascular, Inc.) USD 75.58 -0.68% · AZTA (Azenta, Inc.) USD 48.69 +6.29% · ATRC (AtriCure, Inc.) USD 55.45 +0.78% · VVVV (vVARDIS Holding AG) USD 15.48 -6.18% · WRBY (Warby Parker Inc.) USD 28.2 +8.80% · PLSE (Pulse Biosciences, Inc) USD 45.83 +2.21%

## More
Full page: https://nexqual.com/ZJYL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ZJYL's own 20-F filed 2026-02-10 (https://www.sec.gov/Archives/edgar/data/1837821/000121390026013870/ea0273234-20f_jinmedical.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Nissin Medical Industries | "We have one large customer, Nissin, with whom we generated substantial revenue each year." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-30 | 6-K | Current report (foreign issuer) · period ended Oct 30, 2026 | https://www.sec.gov/Archives/edgar/data/1837821/000121390026114281/0001213900-26-114281-index.htm |
| 2026-09-25 | Schedule 13D/A | Erqi Wang, JOLLY HARMONY ENTERPRISES Ltd: 3.4% of shares, 5%+ holder that may seek to influence the company (amended) — “The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting…” | https://www.sec.gov/Archives/edgar/data/1837821/000121390026103303/0001213900-26-103303-index.htm |
| 2026-09-24 | 6-K | Current report (foreign issuer) · period ended Sep 24, 2026 | https://www.sec.gov/Archives/edgar/data/1837821/000121390026103071/0001213900-26-103071-index.htm |
| 2026-09-08 | 6-K | Current report (foreign issuer) · period ended Sep 8, 2026 | https://www.sec.gov/Archives/edgar/data/1837821/000121390026098090/0001213900-26-098090-index.htm |
| 2026-08-21 | Schedule 13D | Wang Erqi, JOLLY HARMONY ENTERPRISES Ltd: 6.8% of shares, 5%+ holder that may seek to influence the company — “The information set forth in or incorporated by reference into Item 3 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 4. The transactions described in Item 3 were undertaken in connection with the Issuer's recapitalization and its…” | https://www.sec.gov/Archives/edgar/data/1837821/000121390026092631/0001213900-26-092631-index.htm |
| 2026-08-18 | Schedule 13G | NOVASTRALIST HORIZON LTD., Chang Gil LEE: 10.5% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1837821/000118518526003602/0001185185-26-003602-index.htm |
| 2026-08-04 | 6-K | Current report (foreign issuer) · period ended Mar 31, 2026 | https://www.sec.gov/Archives/edgar/data/1837821/000121390026085283/0001213900-26-085283-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
